Literature DB >> 10584260

[Genotype-phenotype correlation in myotonic dystrophy and prediction of clinical seriousness].

T García-Gómez1, J Maestre, M L Garrido, R Vilches, M D Fernández, A Mínguez, P Serrano.   

Abstract

INTRODUCTION: Since description of the expansion of the number of CTG trinucleotides on the long arm of chromosome 19 in the 19 q 13.2-13.3 interval as being responsible for myotonic dystrophy (DM), many studies have established a direct relationship between the size of the expansion and the severity of the manifestations.
OBJECTIVES: To evaluate the clinico-genetic correlation in a population with DM in Eastern Andalucia and to establish the predictive value of the increase in number of CTG repetitions with regard to clinical gravity. PATIENTS AND METHODS: A transverse study of persons from families known to have members with DM, classified with regard to the clinical gravity of their illness. Diagnosis was by means of clinical neurological, ophthalmological and neurophysiological examination and subsequently by genetico-molecular study, Southern blot, PCR, oligonucleotide CTC hybridization and Northern blot.
RESULTS: Genetic studies confirmed the previous clinical diagnosis of DM in 78 persons, of the 145 studied, who came from 32 families. The average size of the mutation was 1-5 kb. There was close correlation between the size of the expansion and the clinical condition. Logistic repression studies permitted adequate classification in function of the size of the expansion in 87.23% of the cases of clinically relevant illness and in 90% of the cases in which the condition was not clinically relevant.
CONCLUSIONS: There is a strong association between the clinical features of DM and the magnitude of the mutation. The size of the expansion has considerable predictive value in prognosis of the disorder. This may be useful when making decisions during prenatal diagnosis.

Entities:  

Mesh:

Year:  1999        PMID: 10584260

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  3 in total

1.  Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia.

Authors:  Josef Finsterer; Georg Safoschnik; Martina Witsch-Baumgartner
Journal:  SAGE Open Med Case Rep       Date:  2017-04-10

2.  The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care.

Authors:  Marie De Antonio; Céline Dogan; Ferroudja Daidj; Bruno Eymard; Jack Puymirat; Jean Mathieu; Cynthia Gagnon; Sandrine Katsahian; Dalil Hamroun; Guillaume Bassez
Journal:  Orphanet J Rare Dis       Date:  2019-06-03       Impact factor: 4.123

3.  Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study.

Authors:  Celine Dogan; Marie De Antonio; Dalil Hamroun; Hugo Varet; Marianne Fabbro; Felix Rougier; Khadija Amarof; Marie-Christine Arne Bes; Anne-Laure Bedat-Millet; Anthony Behin; Remi Bellance; Françoise Bouhour; Celia Boutte; François Boyer; Emmanuelle Campana-Salort; Françoise Chapon; Pascal Cintas; Claude Desnuelle; Romain Deschamps; Valerie Drouin-Garraud; Xavier Ferrer; Helene Gervais-Bernard; Karima Ghorab; Pascal Laforet; Armelle Magot; Laurent Magy; Dominique Menard; Marie-Christine Minot; Aleksandra Nadaj-Pakleza; Sybille Pellieux; Yann Pereon; Marguerite Preudhomme; Jean Pouget; Sabrina Sacconi; Guilhem Sole; Tanya Stojkovich; Vincent Tiffreau; Andoni Urtizberea; Christophe Vial; Fabien Zagnoli; Gilbert Caranhac; Claude Bourlier; Gerard Riviere; Alain Geille; Romain K Gherardi; Bruno Eymard; Jack Puymirat; Sandrine Katsahian; Guillaume Bassez
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.